EMCDDA. New drugs in Europe, 2011, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Apr 2012. 401 kB.
Kneisel, S; Auwärter, V; Kempf, J. Analysis of 30 synthetic cannabinoids in oral fluid using liquid chromatography-electrospray ionization tandem mass spectrometry Drug Test. Anal., 1 Aug 2013, 5 (8), 657-669. 285 kB. https://doi.org/10.1002/dta.1429
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: Origins In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 165-190. 906 kB. https://doi.org/10.1007/164_2018_143 #60
Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report) Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #3. RCS-4 ortho isomer
Banister, SD; Stuart, J; Conroy, T; Longworth, M; Manohar, M; Beinat, C; Wilkinson, SM; Kevin, RC; Hibbs, DE; Glass, M; Connor, M; McGregor, IS; Kassiou, M. Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues Forensic Toxicol., 1 Jul 2015, 33 (2), 355–366. 931 kB. https://doi.org/10.1007/s11419-015-0282-9 #RCS-2 GC,MS,NMR,IR,UV,other